Milbrandt Melissa, Winter Anke C, Nevin Remington L, Pakpahan Ratna, Bradwin Gary, De Marzo Angelo M, Elliott Debra J, Gaydos Charlotte A, Isaacs William B, Nelson William G, Rifai Nader, Sokoll Lori J, Zenilman Jonathan M, Platz Elizabeth A, Sutcliffe Siobhan
Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.
Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri.
Prostate. 2017 May;77(13):1325-1334. doi: 10.1002/pros.23392. Epub 2017 Jul 12.
To investigate mechanisms underlying our previous observation of a large rise in serum prostate-specific antigen, a marker of prostate pathology, during both sexually transmitted and systemic infections, we measured serum high-sensitivity C-reactive protein (hsCRP), a marker of systemic inflammation, in our previous case-control study of young, male US military members and compared our findings to those for PSA.
We measured hsCRP before and during infection for 299 chlamydia, 112 gonorrhea, and 59 non-chlamydial, non-gonococcal urethritis (NCNGU) cases; before and after infection for 55 infectious mononucleosis (IM) and 90 other systemic/non-genitourinary cases; and for 220-256 controls.
Only gonorrhea cases were significantly more likely to have a large hsCRP rise (≥1.40 mg/L or ≥239%) during infection than controls (P < 0.01). However, gonorrhea, IM, and other systemic/non-genitourinary cases were more likely to have a rise of any magnitude up to one year post-diagnosis than controls (p = 0.038-0.077).
These findings, which differ from those for PSA, suggest distinct mechanisms of elevation for hsCRP and PSA, and support both direct (eg, prostate infection) and indirect (eg, systemic inflammation-mediated prostate cell damage) mechanisms for PSA elevation. Future studies should explore our PSA findings further for their relevance to both prostate cancer screening and risk.
为了探究我们之前观察到的血清前列腺特异性抗原(一种前列腺病理学标志物)在性传播感染和全身感染期间大幅升高的潜在机制,我们在之前一项针对年轻美国男性军人的病例对照研究中测量了血清高敏C反应蛋白(hsCRP,一种全身炎症标志物),并将我们的研究结果与前列腺特异性抗原(PSA)的结果进行了比较。
我们测量了299例衣原体感染、112例淋病以及59例非衣原体、非淋菌性尿道炎(NCNGU)病例在感染前和感染期间的hsCRP;55例传染性单核细胞增多症(IM)和90例其他全身/非泌尿生殖系统病例在感染前和感染后的hsCRP;以及220 - 256名对照者的hsCRP。
只有淋病病例在感染期间hsCRP大幅升高(≥1.40mg/L或≥239%)的可能性显著高于对照组(P < 0.01)。然而,淋病、IM以及其他全身/非泌尿生殖系统病例在诊断后长达一年的时间里hsCRP出现任何幅度升高的可能性均高于对照组(p = 0.038 - 0.077)。
这些与PSA不同的研究结果表明,hsCRP和PSA升高的机制不同,并支持PSA升高的直接机制(如前列腺感染)和间接机制(如全身炎症介导的前列腺细胞损伤)。未来的研究应进一步探索我们关于PSA的研究结果与前列腺癌筛查和风险的相关性。